APA (7th ed.) Citation

Arjun Bhadhuri, Daniel Dröschel, Mike Guldimann, Claudia Jetschgo, Judit Banhazi, Matthias Schwenkglenks, & C. Simone Sutherland. (2022). Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland. BMC.

Chicago Style (17th ed.) Citation

Arjun Bhadhuri, Daniel Dröschel, Mike Guldimann, Claudia Jetschgo, Judit Banhazi, Matthias Schwenkglenks, and C. Simone Sutherland. Cost-effectiveness of Voretigene Neparvovec in the Treatment of Patients with Inherited Retinal Disease with RPE65 Mutation in Switzerland. BMC, 2022.

MLA (9th ed.) Citation

Arjun Bhadhuri, et al. Cost-effectiveness of Voretigene Neparvovec in the Treatment of Patients with Inherited Retinal Disease with RPE65 Mutation in Switzerland. BMC, 2022.